Activation of peptide prodrugs by hK2
US8450280B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 16, 2012 |
| Grant date | May 28, 2013 |
| Priority date | — |
| Expiry date | May 16, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/47
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.